/ricerca/ansaen/search.shtml?any=
Show less

Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Italians find effective anti-cancer vaccine

Italians find effective anti-cancer vaccine

Uses virus as trojan horse to boost immune response

ROME, 11 August 2022, 15:34

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

An Italian research group has found an anti-cancer vaccine able to trigger immune responses to tumours and which may boost the efficacy of immune therapy drugs.
    The discovery was made by Armenise-Harvard immuno regulatory researchers at the Italian Institute for Genomic Medicine (IIGM).
    The vaccine uses a virus as a trojan horse, they said.
    It instructs the immune system to recognize cancer cells.
    The research team is based at the IRCCS Oncology Foundation of Piedmont at Candiolo outside Turin.
    The discovery was illustrated in a paper published in the journal Science Translational Medicine.
    It was realized in collaboration with the Swiss/Italian biotech company Nouscom.
    The vaccine proved effective, in association with an immuno therapy drug, on 12 patients with a sub-type of colon cancer in the metastatic phase.
    "I consider that the technique for realizing these vaccines has been decidedly proven and that the data obtained in the first clinical trials are very promising," said Armenise-Harvard lab chief Luigia Pace.
    "There is now a concrete possibility of creating new vaccines which will be effective against many other types of cancer".
   
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.